Sofosbuvir-based direct acting antiviral therapies for patients with hepatitis C virus genotype 2 infection
Journal
Journal of Gastroenterology and Hepatology (Australia)
Journal Volume
34
Journal Issue
9
Pages
1620-1625
Date Issued
2019
Abstract
Background and Aim: Data regarding the comparative effectiveness and safety of sofosbuvir (SOF) in combination with ribavirin (RBV), daclatasvir (DCV), or ledipasvir (LDV) for hepatitis C virus genotype 2 (HCV-2) patients were limited. We aimed to evaluate the performance of these regimens in Taiwan. Methods: One hundred eighty-seven HCV-2 patients with compensated liver diseases receiving SOF in combination with RBV (n?=?82), DCV (n?=?66), or LDV (n?=?39) for 12?weeks were retrospectively enrolled. The effectiveness was determined by sustained virologic response 12?weeks off therapy (SVR12). The patient characteristics potentially related to SVR12 were compared. The safety profiles and laboratory abnormalities were assessed. Results: The SVR12 rates were 93.9% (95% confidence interval [CI]: 86.5–97.4%), 98.5% (95% CI: 91.9–99.7%), and 100% (95% CI: 91.0–100%) in patients receiving SOF combined with RBV, DCV, and LDV, respectively. All patients tolerated treatment well. The stratified SVR12 rates were comparable regardless of baseline characteristics or week 4 viral decline among these regimens. Six (3.2%) patients had serious adverse events which were not related to treatment. The rates of fatigue, pruritus, and anemia tended to be higher in patients receiving RBV (22.0%, 19.5%, and 8.5%) combination than those receiving DCV (10.6%, 6.1%, and 1.5%) or LDV (10.3%, 5.1%, and 0%) combination. Conclusions: Sofosbuvir in combination with RBV, DCV, or LDV for 12?weeks is effective and well-tolerated for HCV-2 patients. Compared with DCV or LDV combination, the risks of fatigue, pruritus, and anemia are higher in patients receiving RBV combination. ? 2019 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd
SDGs
Other Subjects
antivirus agent; benzimidazole derivative; daclatasvir; fluorene derivative; imidazole derivative; ledipasvir, sofosbuvir drug combination; ribavirin; sofosbuvir; uridine phosphate; aged; chronic hepatitis C; comparative effectiveness; comparative study; drug effect; female; genetics; genotype; Hepacivirus; human; male; middle aged; retrospective study; sustained virologic response; Taiwan; time factor; treatment outcome; virology; Aged; Antiviral Agents; Benzimidazoles; Comparative Effectiveness Research; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Retrospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Taiwan; Time Factors; Treatment Outcome; Uridine Monophosphate
Publisher
Blackwell Publishing
Type
journal article